Correction: Screening for prostate cancer: US preventive services recommendation statement(JAMA - Journal of the American Medical Association (2018) 319: 18 (1901-1913) DOI: 10.1001/jama.2018.3710);Screening for prostate cancer USPreventive servicestaskforcerecommendation statement

JAMA - Journal of the American Medical Association

Volumn 319, Issue 18, 2018, Pages 1901-1913

  Grossman, David C ^a   Curry, Susan J ^b   Owens, Douglas K ^c,d   Bibbins Domingo, Kirsten ^e   Caughey, Aaron B ^f   Davidson, Karina W ^g   Doubeni, Chyke A ^h   Ebell, Mark ⁱ   Epling, John W ^j   Kemper, Alex R ^k   Krist, Alex H ^l,m   Kubik, Martha ⁿ   Seth Landefeld, C ^o   Mangione, Carol M ^p   Silverstein, Michael ^q   Simon, Melissa A ^r   Siu, Albert L ^s,t   Tseng, Chien Wen ^u,v  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Columbia University ^*  (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF GEORGIA   (United States)

^j VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^k NATIONWIDE CHILDREN S HOSPITAL   (United States)

^l Fairfax Family Practice Residency   (United States)

^m VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁿ TEMPLE UNIVERSITY   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q BOSTON UNIVERSITY   (United States)

^r NORTHWESTERN UNIVERSITY   (United States)

^s MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^t VETERANS AFFAIRS MEDICAL CENTER   (United States)

^u UNIVERSITY OF HAWAII   (United States)

^v PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER SCREENING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; ETHNICITY; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; FALSE POSITIVE RESULT; FAMILY HISTORY; HEALTH HAZARD; HIGH RISK PATIENT; HUMAN; INTESTINE FUNCTION DISORDER; MALE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; UNITED STATES; URINE INCONTINENCE; AGE; BLOOD; EARLY CANCER DIAGNOSIS; MIDDLE AGED; PRACTICE GUIDELINE; PROCEDURES; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR; STANDARDS;

AGE FACTORS; AGED; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 85046771906     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.7453     Document Type: Erratum

References (43)

1. National Cancer Institute. Cancer stat facts: prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html. Accessed March 8, 2018.
2. Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int J Cancer. 2015;137 (12):2795-2802.
3. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 154. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-1.
4. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force [published online May 8, 2018]. JAMA. doi:10.1001/jama.2018.3712
5. Kilpeläinen TP, Tammela TL, Roobol M, et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer. 2011;47(18):2698-2705.
6. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484-e492.
7. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592-599.
8. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959): 2027-2035.
9. Kilpeläinen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105(10):719-725.
10. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354-360.
11. Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developingmetastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62(5): 745-752.
12. Martin RM, Donovan JL, Turner EL, et al; CAP Trial Group. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. JAMA. 2018;319(9):883-895.
13. Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2014;113(2):254-259.
14. Lin JS, Petitti DB, Burda BU. Overview of Prostate Cancer Screening Decision Models: A Contextual Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-2.
15. Hamdy FC, Donovan JL, Lane JA, et al; ProtecT Study Group. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424.
16. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.
17. Andriole GL, Crawford ED, Grubb RL III, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
18. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78-85.
19. Saarimäki L, Tammela TL, Määttänen L, et al. Family history in the Finnish prostate cancer screening trial. Int J Cancer. 2015;136(9):2172-2177.
20. National Cancer Institute. Genetics of prostate cancer (PDQ®)-health professional version. https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq. Accessed March 8, 2018.
21. Liss MA, Chen H, Hemal S, et al. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. J Urol. 2015;193(1):75-79.
22. Centers for Disease Control and Prevention. United States cancer statistics: 1999-2014 cancer incidence and mortality data. https://nccd.cdc.gov/uscs/. Accessed March 8, 2018.
23. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-1337.
24. Petitti DB, Lin JS, Burda BU. Overdiagnosis in Prostate Cancer Screening Decision Models: A Contextual Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-3.
25. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126(10):2387-2393.
26. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303-311.
27. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
28. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
29. Wilt TJ, Jones KM, BarryMJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132-142.
30. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344: d7894.
31. Walter LC, Fung KZ, Kirby KA, et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 2013;173(10):866-873.
32. Raaijmakers R, KirkelsWJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60(5):826-830.
33. Fowler FJ Jr, BarryMJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006;21 (7):715-721.
34. Brindle LA, Oliver SE, Dedman D, et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int. 2006;98(4): 777-782.
35. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology. 2007;69(2):215-220.
36. Donovan JL, Hamdy FC, Lane JA, et al; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425-1437.
37. Johansson E, Steineck G, Holmberg L, et al; SPCG-4 Investigators. Long-Term quality-of-life outcomes after radical prostatectomy or watchful waiting: The Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12(9):891-899.
38. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
39. American Academy of Family Physicians. Clinical preventive service recommendation: prostate cancer. https://www.aafp.org/patient-care/clinical-recommendations/all/prostate-cancer.html. 2012. Accessed March 8, 2018.
40. Bell N, Connor Gorber S, Shane A, et al; Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225-1234.
41. Qaseem A, BarryMJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158 (10):761-769.
42. Carter HB, Albertsen PC, BarryMJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419-426.
43. American Cancer Society. American Cancer Society recommendations for prostate cancer early detection. https://www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html. 2016. Accessed March 8, 2018.